Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Arcellx Inc today and set a price target of $112.00. The company’s shares closed yesterday at $82.24.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Gerberry is a 4-star analyst with an average return of 5.7% and a 53.18% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Alkermes, and Arrowhead Pharmaceuticals.
Arcellx Inc has an analyst consensus of Strong Buy, with a price target consensus of $116.27, a 41.38% upside from current levels. In a report released on September 23, Canaccord Genuity also maintained a Buy rating on the stock with a $121.00 price target.
Based on Arcellx Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $8.13 million and a GAAP net loss of $62.27 million. In comparison, last year the company earned a revenue of $39.26 million and had a GAAP net loss of $7.2 million
Read More on ACLX:
Disclaimer & DisclosureReport an Issue
- Arcellx Inc’s Strong Positioning and Financial Stability Support Buy Rating Amid Anticipated FDA Approval
- 3 Stocks to Buy Now, According to the Technical Analysis
- Promising Clinical Outcomes and Low Toxicity Profile Position Anito-cel as a Leading Therapy for Relapsed/Refractory Multiple Myeloma
- Arcellx, Inc. Reports Increased Losses Amid Rising R&D Costs
- Promising Prospects for Arcellx Inc: Strong Efficacy and Strategic Partnerships Drive Buy Rating
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)